Results saw all 24 healthy volunteers who made it to the 72-week mark still had effective levels of dMAb in their systems.

Amgen’s Uplizna (inebilizumab-cdon) has shown sustained efficacy in a group of gMG patients after 52 weeks in a Phase III ...

The company’s weight loss therapy was able to sustain itself for up to 40 days in obese patients after a single injection.

Amgen and Kyowa Kirin have reported that the 24-week Phase III IGNITE trial assessing two dose strengths of rocatinlimab, in ...

Everest Medicines has dosed the first subject with EVM16, the company’s personalised mRNA cancer vaccine, in the EVM16CX01 ...

Tris Pharma previously announced data from another Phase III trial of cebranopadol, which also met its primary endpoint.

Merck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...

Persica's antibiotic-based drug could benefit patients with chronic lower back pain who are suffering from an infection in ...

The US FDA has ordered BioNTech to immediately halt its Phase I/II trial of BNT165e, a malaria vaccine candidate, pending ...

Amgen and AstraZeneca have reported outcomes from the WAYPOINT trial of Tezspire for treating chronic rhinosinusitis with ...

AstraZeneca has reported positive “high-level” outcomes from the Phase III MATTERHORN trial of Imfinzi (durvalumab) with FLOT chemotherapy.

Biohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint in a pivotal Phase II/III bipolar trial.